Comera Life Sciences Holdings Inc

Chart & performance

D1W1MN

P/E

—

P/S

0.00

EPS

—

Div yield, %

—

Shrs. gr., 5y

—

Rev. gr., 5y

Revenues

633k

+97.95%

Net income

-18m

L+230.24%

CFO

-10m

L+160.03%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Comera Life Sciences Holdings, Inc. is an early-stage biotechnology firm focused on creating its own pipeline of innovative therapies. These treatments leverage its exclusive SQore formulation platform, engineered to transform intravenous (IV) biologic drugs into more convenient subcutaneous (SQ) injectable forms. Currently, the company is progressing two main product candidates: CLS-001, an early-stage "biobetter" designed to treat inflammatory bowel conditions like Crohn's and Ulcerative Colitis, and CLS-002, another preclinical biobetter aimed at diverse oncology indications. Established in 2014, Comera Life Sciences is headquartered in Woburn, Massachusetts.

Key people

Michael Campbell

Chief Executive Officer, Chief Financial Officer · since 2024

Janice Mccourt

Chief Business Officer · since 2022

Roopom Banerjee